Bank of America’s Ionis Pharmaceuticals IONS Stock Holding History

Bank of America’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-45,000	Closed	-$2.94M	–	7844
2025 Q3	$2.94M	Buy	+45,000	New	+$2.2M	﹤0.01%	4482
2022 Q3	–	Sell	-35,000	Closed	-$1.3M	–	8010
2022 Q2	$1.3M	Hold	35,000	–	–	﹤0.01%	4669
2022 Q1	$1.3M	Buy	+35,000	New	+$1.15M	﹤0.01%	4987
2019 Q1	–	Sell	-342,100	Closed	-$18.5M	–	7248
2018 Q4	$18.5M	Buy	+342,100	New	+$17.4M	﹤0.01%	1727
2015 Q1	–	Sell	-10,200	Closed	-$630K	–	7293
2014 Q4	$630K	Sell	10,200 -51,600	-83%	-$2.55M	﹤0.01%	4419
2014 Q3	$2.4M	Buy	61,800 +41,800	+209%	+$1.48M	﹤0.01%	3219
2014 Q2	$689K	Sell	20,000 -59,000	-75%	-$1.86M	﹤0.01%	4317
2014 Q1	$3.41M	Buy	79,000 +41,300	+110%	+$2M	﹤0.01%	2738
2013 Q4	$1.5M	Buy	37,700 +10,100	+37%	+$360K	﹤0.01%	3622
2013 Q3	$1.04M	Sell	27,600 -4,400	-14%	-$131K	﹤0.01%	3917
2013 Q2	$860K	Buy	+32,000	New	+$680K	﹤0.01%	4202

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America's IONS Position: Q1 2026 in Review

Bank of America increased its Ionis Pharmaceuticals (IONS) stake by 7.3% in Q1 2026, buying an estimated $4.5M and bringing the position to 840,598 shares worth $63.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1444.

Bank of America first reported a position in IONS in Q2 2013 and has held it in 52 quarters since. The position peaked at $71.7M in Q3 2017. 494 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Bank of America held 840,598 shares of Ionis Pharmaceuticals worth $63.1M as of Q1 2026.
Bank of America bought 57,019 Ionis Pharmaceuticals shares in Q1 2026, an estimated $4.5M.
Ionis Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1444 holding.
Bank of America first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Bank of America's Ionis Pharmaceuticals position peaked at $71.7M in Q3 2017.
494 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.